Key Considerations for your Gene Therapy Product Launch

Product Launch Webinar Series

 
Home / Commercial Services /

Key Considerations for your Gene Therapy Product Launch

Throughout this webinar our experts and client guest speaker, Ian Mussen, Head of Supply Chain EMEA, Novartis Gene Therapies will share valuable insight into the key considerations for a successful Gene Therapy product launch.

The presenters will review areas such as developing bespoke packaging processes to facilitate in most cases, Ultra Low Temperature handling requirements and the various Just in Time supply chain models. Ian will join the Almac team to share his real-life experience of successfully launching Zolgensma onto the EU market including the approach Novartis Gene Therapies took to ensure a smooth launch and what lessons were learnt along the way.

Thursday 17th June, 3pm BST

Speakers: Robert O’Brien, Head of Technical Support and Ian Mussen, Head of Supply Chain EMEA, Novartis Gene Therapies

Robert O’Brien

Head of Technical Support
Education: BSc Chemistry; Diploma Packaging Development Technology

Robert has almost 20 years’ experience in managing commercial product launches in both pharmaceutical and FMCG industries. Over this period, he has led multi-disciplinary teams to support a number of challenging, but ultimately, successful, global product launches and transition into on-going commercial supply. Leading the Technical Support function within Almac Commercial Packaging, he and his team are responsible for end-to-end operational launch. From product & process design, through validation requirements to timely commercial production and launch.

After graduating from University of Liverpool, Robert spent the majority of his career in the soft drink industry working for both Coca-Cola and Britvic plc on national and international developments and product launches, before transferring to pharmaceuticals.

Ian Mussen

Head of Supply Chain EMEA, Novartis Gene Therapies
Ian has over 20 years’ experience in global supply chain operations with the last 13 in Biotech, predominantly establishing and building manufacturing and supply operations, leading to subsequent product and market launches.
This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies